Patents by Inventor Haiping LIANG

Haiping LIANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240010643
    Abstract: A preparation method of substituted pyrimidine piperazine compounds, as well as intermediate compounds used in the method. The preparation method has the advantages of cheap and easily available raw materials, mild conditions, short reaction time, safety and controllability, high total yield, which is especially suitable for industrial production.
    Type: Application
    Filed: September 16, 2021
    Publication date: January 11, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chuanfei JIN, Haiping LIANG, Tengfei XU, Yingjun ZHANG
  • Patent number: 11285153
    Abstract: A substituted pyrimidine piperazine compound and uses thereof, and a pharmaceutical composition containing the compound and uses thereof. Wherein the compound has Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted pyrimidine piperazine compound and the pharmaceutical composition containing the compound can be used to inhibit 5-hydroxytryptamine reuptake and/or activate the 5-HT1A receptors. Also, a method of preparing such compounds and pharmaceutical compositions, and uses thereof in the treatment of central nervous system dysfunction.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: March 29, 2022
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chuanfei Jin, Wenhe Zhong, Haiping Liang, Yingjun Zhang
  • Publication number: 20200276196
    Abstract: A substituted pyrimidine piperazine compound and uses thereof, and a pharmaceutical composition containing the compound and uses thereof. Wherein the compound has Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted pyrimidine piperazine compound and the pharmaceutical composition containing the compound can be used to inhibit 5-hydroxytryptamine reuptake and/or activate the 5-HT1A receptors. Also, a method of preparing such compounds and pharmaceutical compositions, and uses thereof in the treatment of central nervous system dysfunction.
    Type: Application
    Filed: September 21, 2018
    Publication date: September 3, 2020
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Chuanfei JIN, Wenhe ZHONG, Haiping LIANG, Yingjun ZHANG
  • Patent number: 10316025
    Abstract: The invention relates to substituted piperazine compounds and methods of use and uses thereof, and further to the pharmaceutical compositions comprising the compounds and uses thereof, wherein the compound has Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted piperazine compounds and pharmaceutical compositions comprising the compounds disclosed herein can be used for inhibiting 5-hydroxytryptamine reuptake and/or stimulating 5-HT1A receptors. The invention also relates to processes for preparing these compounds and pharmaceutical compositions, and their uses in the treatment of a central nervous system dysfunction.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: June 11, 2019
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Chuanfei Jin, Haiping Liang, Chao Yi, Ji Zhang
  • Publication number: 20180179188
    Abstract: The invention relates to substituted piperazine compounds and methods of use and uses thereof, and further to the pharmaceutical compositions comprising the compounds and uses thereof, wherein the compound has Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted piperazine compounds and pharmaceutical compositions comprising the compounds disclosed herein can be used for inhibiting 5-hydroxytryptamine reuptake and/or stimulating 5-HT1A receptors. The invention also relates to processes for preparing these compounds and pharmaceutical compositions, and their uses in the treatment of a central nervous system dysfunction.
    Type: Application
    Filed: June 2, 2016
    Publication date: June 28, 2018
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun ZHANG, Chuanfei JIN, Haiping LIANG, Chao YI, Ji ZHANG